Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial.
Patricia Rieken Macêdo RoccoPedro Leme SilvaFernanda F CruzMarco Antonio C Melo-JuniorPaulo F G M M TiernoMarcos A MouraLuís Frederico G De OliveiraCristiano C LimaEzequiel Aparecido Dos SantosWalter F JuniorAna Paula S M FernandesKleber G FranchiniErick MagriNara F de MoraesJosé Mário J GonçalvesMelanie N CarbonieriIvonise S Dos SantosNatália F PaesPaula V M MacielRaissa P RochaAlex F de CarvalhoPedro Augusto AlvesJosé Luis Proença ModenaArtur T CordeiroDaniela B B TrivellaRafael Elias MarquesRonir R LuizPaolo PelosiJose Roberto Lapa E Silvanull nullPublished in: The European respiratory journal (2021)
In patients with mild COVID-19, symptom resolution did not differ between nitazoxanide and placebo groups after 5 days of therapy. However, early nitazoxanide therapy was safe and reduced viral load significantly.